Patient characteristics | Mean ± standard deviation or frequency (%) |
---|---|
Age at diagnosis (years) (n = 994) | 50.4 ± 9.6 |
Body mass index (kg/m2) (n = 981) | 24.9 ± 4.1 |
Body surface area (m2) (n = 993) | 1.7 ± 0.1 |
Tumour characteristics | |
Tumor status | 994 (100) |
- Primary tumour | 966 (97.2) |
- Relapsed tumour | 28 (2.8) |
Tumour gradea | 979 (98.5) |
- 1 | 39 (4.0) |
- 2 | 334 (34.1) |
- 3 | 606 (61.9) |
Tumour type | 994 (100) |
- Invasive ductal carcinoma | 823 (82.8) |
- Invasive lobular carcinoma | 103 (10.4) |
- Mixed | 27 (2.7) |
- Others | 41 (4.1) |
Tumour stageb | 978 (98.4) |
- I | 113 (11.5) |
- IIA | 306 (31.3) |
- IIB | 245 (25.1) |
- IIIA | 193 (19.7) |
- IIIB | 44 (4.5) |
- IIIC | 77 (7.9) |
Receptor status | |
- Estrogen receptor positive | 683 (68.8) |
- Progesterone receptor positive | 577 (58.1) |
- HER2 positive | 205 (20.7) |
Subtypec | 981 (98.7) |
- Luminal A | 325 (33.1) |
- Luminal B HER2- | 234 (23.9) |
- Luminal B HER2+ | 121 (12.3) |
- HER2-like | 84 (8.6) |
- Triple negative | 217 (22.1) |
Nottingham Prognostic Index (NPI)d (n = 757) | 5.0 ± 0.9 |
Chemotherapy characteristics | |
Chemotherapy setting | 994 (100) |
- Adjuvant | 874 (87.9) |
- Neoadjuvant | 120 (12.1) |
Planned cycles of FEC chemotherapy | 994 (100) |
- 3 cycles FEC | 559 (56.2) |
- 4 or 5 cycles FEC | 2 (0.2) |
- 6 cycles FEC | 433 (43.6) |
Relative dose intensity (RDI) (n = 994) | 0.96 ± 0.1 |
Growth factor use | 994 (100) |
- Primary | 15 (1.5) |
- Secondary | 325 (32.7) |
- None | 654 (65.8) |
Baseline laboratory parameters | |
White blood cell count (109/L) (n = 985) | 7.2 ± 2.0 |
Absolute neutrophil count (109/L) (n = 937) | 4.4 ± 1.6 |
Haemoglobin (g/dl) (n = 989) | 13.3 ± 1.0 |
Platelets (109/L) (n = 985) | 275.4 ± 65.1 |
Total bilirubin (mg/dl) (n = 915) | 0.4 ± 0.2 |
Creatinine (mg/dl) (n = 957) | 0.8 ± 0.1 |
Alanine aminotransferase (U/L) (n = 955) | 23.3 ± 15.3 |
Aspartate aminotransferase (U/L) (n = 955) | 21.9 ± 11.1 |
FEC chemotherapy toxicities | |
Febrile neutropenia | 166 (16.7) |
- Febrile neutropenia in first cycle | 107 (10.7) |
Prolonged (≥ 5 days) grade 4 neutropenia | 345 (34.7) |
Deep neutropenia (< 100/μl) | 93 (9.4) |
Other grade 3–4 toxicities | 46 (4.6) |